Glaucoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Thus present study aimed to analyze the association of TNF-α promoter region alterations (c.-238G>A (rs361525), c.-308G>A (rs1800629), c.-857C>T (rs1799724) and c.-863C>A (rs1800630)) with glaucoma in north Indian cohort.
|
31132515 |
2019 |
Glaucoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: BCVA: best corrected visual acuity; BMI: body mass index; CDR: cup-to-disc ratio; EDTA: ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; ESR: erythrocyte sedimentation rate; HVF: Humphrey visual field; IOP: intraocular pressure; KPro G: keratoprosthesis with glaucoma; KPro NoG: keratoprosthesis without glaucoma; KPro: keratoprosthesis; MD: mean deviation; NA: narrow angle; non-KPro: without keratoprosthesis; PACG: primary angle closure glaucoma; RNFL: retinal nerve fiber layer; TNF-α: tumor necrosis factor alpha; TNFR1: tumor necrosis factor receptor 1; TNFR2: tumor necrosis factor receptor 2.
|
30632412 |
2019 |
Glaucoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Pre-treatment of the glaucoma mice with ASIB leads to inhibition of TNF-α and IL-6 production.
|
31093481 |
2019 |
Glaucoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
Myricetin effectively prevented IOP elevation in glaucoma-induced rats and decreased inflammatory cytokines (IL-1α, IL-1β, IL-6, Il-8, TNF-α) in the aqueous humor and POAG TM cells of glaucoma-induced rats.
|
30473883 |
2018 |
Glaucoma
|
0.300 |
Biomarker
|
disease |
BEFREE |
IL-17, IL-6 and TNF-α presented good diagnostic values for glaucoma.
|
29285128 |
2017 |
Glaucoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The combined results showed that the TNF-α -308G/A gene polymorphism was significantly associated with risks of high-tension glaucoma (A versus G: OR=1.660, 95% CI=1.033-2.667; AA/AG versus GG: OR=1.713, 95% CI=1.10-2.651), but not with normal tension glaucoma or exfoliation glaucoma.
|
23559847 |
2013 |
Glaucoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to clarify the effect of the TNF-α -308G/A polymorphism on glaucoma risk.
|
21701244 |
2012 |
Glaucoma
|
0.300 |
Biomarker
|
disease |
RGD |
Here, using a rat model of glaucoma, we investigated the source of elevated TNF-α and examined whether Etanercept, a TNF-α blocker that is in common clinical use for other indications, is protective against RGC death.
|
22802951 |
2012 |
Glaucoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Frequency of TNF-α -308 G/A and TNF-α -238 G/A promoter polymorphisms in glaucoma and healthy subjects.
|
21575121 |
2012 |
Glaucoma
|
0.300 |
Biomarker
|
disease |
RGD |
In rats with glaucoma, the pharmacologic use of TrkC antagonists delayed RGC death and reduced the production of retinal TNF-α.
|
20574020 |
2010 |
Glaucoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Association of tumor necrosis factor alpha gene polymorphism G-308A with pseudoexfoliative glaucoma in the Pakistani population.
|
20029655 |
2009 |
Glaucoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Of interest, the distribution of TNFA genotypes was significantly different between patients with primary open-angle glaucoma (p = 0.001) or pseudoexfoliative glaucoma (p = 0.001) and controls, while no difference was found when chronic angle-closure glaucoma patients were compared to controls (p = 0.72).
|
19556827 |
2009 |
Glaucoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that TNF-alpha-308 G/A genotype is not associated with PEX glaucoma.
|
18852869 |
2008 |
Glaucoma
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Optineurin negatively regulates TNFalpha- induced NF-kappaB activation by competing with NEMO for ubiquitinated RIP.
|
17702576 |
2007 |
Glaucoma
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Statistical analysis showed a possible interaction between polymorphisms in the OPTN and the TNF-alpha genes that would increase the risk for glaucoma.
|
15557444 |
2004 |
Glaucoma
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
To gain insight into the role of OPTN in the development of glaucoma we studied its expression in response to factors known to be associated with the disease: elevated IOP, tumor necrosis factor-alpha (TNFalpha), and dexamethasone (DEX).
|
12379221 |
2002 |